Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 3 art units • 4 examiners • 1 of 7 (14%) have an AI response strategy ready • 3 patents granted in the last 365 days
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has 7 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 4 distinct examiners across 3 art units, showing that several actions share examiner or art-unit context.
SKOKO III, JOHN JOSEPH is the busiest examiner, with 3 pending actions. That concentration supports a coordinated review of those matters for consistent biotechnology claim strategy, disclosure support, and treatment of recurring objections.
The remaining actions should be managed with the same portfolio objectives but separate examiner-specific analysis. Counsel can use common technical terminology where appropriate while adapting arguments and amendments to the applicable art-unit records.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 2 (29%) |
| Double-patenting + other | 3 (43%) |
| Multi-statute (no §101) | 2 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SKOKO III, JOHN JOSEPH | 3 | 53.0% | +55.2% |
| PUTTLITZ, KARL J | 2 | 69.2% | +18.5% |
| CUNNINGCHEN, KATHLEEN MARY | 1 | 62.5% | +60.5% |
| YOO, SUN JAE | 1 | 71.2% | +0.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18559039 | CHEMICAL COUPLING LINKER AND USE THEREOF | YOO, SUN JAE | — |
| 18324511 | ANTI-ERBB2 ANTIBODY-DRUG CONJUGATE AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | PUTTLITZ, KARL J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18155650 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | SKOKO III, JOHN JOSEPH | 14d |
| 17998772 | ANTIBODY DRUG CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | SKOKO III, JOHN JOSEPH | 27d |
| 18648187 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | SKOKO III, JOHN JOSEPH | — |
| 18532359 | COMBINATION THERAPIES FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER | CUNNINGCHEN, KATHLEEN MARY | — |
| 18324511 | ANTI-ERBB2 ANTIBODY-DRUG CONJUGATE AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | PUTTLITZ, KARL J | — |
| 17471653 | ANTI-ERBB2 ANTIBODY-DRUG CONJUGATE AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | PUTTLITZ, KARL J | — |
| Art Unit | Apps |
|---|---|
| 1643 | 3 |
| 1646 | 3 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18648187 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | SKOKO III, JOHN JOSEPH | 1643 | §112DP | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18532359 | COMBINATION THERAPIES FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER | CUNNINGCHEN, KATHLEEN MARY | 1646 | §103§112DP | Non-Final OA | — | Pending | Dec 07, 2023 |
| 18559039 | CHEMICAL COUPLING LINKER AND USE THEREOF | YOO, SUN JAE | 1674 | §102§112 | Non-Final OA | — | Pending | Nov 03, 2023 |
| 18324511 | ANTI-ERBB2 ANTIBODY-DRUG CONJUGATE AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | PUTTLITZ, KARL J | 1646 | §103§112 | Final Rejection | — | Pending | May 26, 2023 |
| 18155650 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | SKOKO III, JOHN JOSEPH | 1643 | §103§112DP | Final Rejection | 14d | Pending | Jan 17, 2023 |
| 17998772 | ANTIBODY DRUG CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | SKOKO III, JOHN JOSEPH | 1643 | DP | Final Rejection | 27d | AI Ready | Nov 14, 2022 |
| 17471653 | ANTI-ERBB2 ANTIBODY-DRUG CONJUGATE AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | PUTTLITZ, KARL J | 1646 | DP | Final Rejection | — | Pending | Sep 10, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has 7 pending office actions as of October 2026, spread across 3 art units and 4 examiners.
John Joseph Skoko III has the most, with 3 of Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
